Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

612
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
612
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

3.9K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.9K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

536
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
536
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.6K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

305
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
305

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mild cognitive impairment in Parkinson's disease: current view.

Frontiers in cognition·2026
Same author

Psychosis in Huntington disease: a short update.

Journal of neural transmission (Vienna, Austria : 1996)·2026
Same author

The enigma of vascular dementia: current state and emerging perspectives.

Journal of neural transmission (Vienna, Austria : 1996)·2026
Same author

Depression and apathy in frontotemporal dementia: a short assessment of facts and outlook.

Journal of neural transmission (Vienna, Austria : 1996)·2026
Same author

Is there a link between multiple sclerosis and Alzheimer disease? A critical note.

Journal of neural transmission (Vienna, Austria : 1996)·2025
Same author

Comorbid Pathologies and Their Impact on Dementia with Lewy Bodies-Current View.

International journal of molecular sciences·2025

Related Experiment Video

Updated: Jul 27, 2025

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

17.4K

Multiple system atrophy - a clinicopathological update.

Kurt A Jellinger1

  • 1Institute of Clinical Neurobiology, Vienna, Austria.

Free Neuropathology
|June 7, 2023
PubMed
Summary
This summary is machine-generated.

Multiple system atrophy (MSA) is a fatal neurodegenerative disease characterized by alpha-synuclein deposits. Research is advancing understanding of its complex pathogenesis and exploring new therapeutic strategies for this incurable disorder.

Keywords:
Animal modelsBiomarkersEtiopathogenesisExperimental therapeuticsGlio-neuronal degenerationMultiple system atrophyPrion-like seedingα-synuclein

More Related Videos

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
08:29

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans

Published on: December 18, 2016

14.1K
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

11.5K

Related Experiment Videos

Last Updated: Jul 27, 2025

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

17.4K
Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
08:29

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans

Published on: December 18, 2016

14.1K
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

11.5K

Area of Science:

  • Neuroscience
  • Pathology
  • Genetics

Background:

  • Multiple system atrophy (MSA) is a fatal, adult-onset neurodegenerative disorder with uncertain etiology.
  • Clinically, it presents with parkinsonism unresponsive to Levo-dopa, cerebellar, motor, and autonomic dysfunction.
  • MSA is an alpha-synucleinopathy involving glioneuronal degeneration in multiple nervous system areas.

Purpose of the Study:

  • To elucidate the molecular mechanisms underlying the progression of Multiple System Atrophy (MSA).
  • To understand the pathogenesis involving alpha-synuclein (αSyn) propagation and cellular dysfunctions.
  • To highlight the need for multidisciplinary research for effective treatment development.

Main Methods:

  • Studies in mouse models and human patients to understand disease progression.
  • Analysis of alpha-synuclein (αSyn) deposition and cell-to-cell spreading.
  • Review of current understanding of pathogenic mechanisms including oxidative stress and neuroinflammation.

Main Results:

  • MSA pathogenesis involves prion-like αSyn spread, oxidative stress, proteasomal and mitochondrial dysfunction, and neuroinflammation.
  • Disease progression leads to neurodegeneration, demyelination, and multisystem involvement.
  • Diagnostic accuracy has improved with biomarkers, though severe dementia is rare.

Conclusions:

  • Multiple system atrophy (MSA) pathogenesis is complex, involving multiple interacting molecular and cellular pathways.
  • Despite improved diagnostics and ongoing clinical trials, effective disease-modifying therapies are still lacking.
  • Urgent multidisciplinary research is needed to uncover the genetic and molecular basis for developing effective treatments for MSA.